Shenzhen Hepalink Invests $69 Million in Canada's Resverlogix

Shenzhen Hepalink announced a US$69 million investment into Canada 's Resverlogix via a private placement that will raise Hepalink's stake in Resverlogix to 45%. Resverlogix is currently conducting a Phase III trial of apabetalone (RVX-208), a first-in-class, small molecule BET (bromodomain and extra-terminal) inhibitor. Resverlogix expects RVX-208 to raise a patient's high-density cholesterol. Hepalink began as a global supplier of heparin API, which is sourced from pig intestines. More details.... Stock Symbols: (SHE: 002399) (TSX: RVX) Share this with colleagues: // //